Business News • PR NewsWire • New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Compared to Stelara® (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis

New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Compared to Stelara® (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis

New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Compared to Stelara® (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis

Lilly to present head-to-head 24-week data comparing the efficacy and safety of Taltz and Stelara for the treatment of moderate-to-severe plaque psoriasis INDIANAPOLIS, March 4, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that patients with...

View More : http://www.prnewswire.com/news-releases/new-head-to-head-data-shows-significantly-higher-response-rates-for-lillys-taltz...

Releted News by prnewswire

Madvapes Registers Products With Europe TPD!

Regeneron and Sanofi Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of DUPIXENT® (dupilumab) in Moderate-to-Severe Atopic Dermatitis

Performance de conscientização "A Better High" da HEAVENSAKE na Catedral Americana em Paris

Fintech Business, Beehive, is the First Peer to Peer Lending Platform to Receive DFSA Regulation

Buckle Me Baby Coats Ends Parents' "No Coat in the Car Seat" Problem